Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
Articolo
Data di Pubblicazione:
2021
Citazione:
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV / González-Cordón, Ana; Assoumou, Lambert; Moyle, Graeme; Waters, Laura; Johnson, Margaret; Domingo, Pere; Fox, Julie; Stellbrink, Hans-Jürgen; Guaraldi, Giovanni; Masiá, Mar; Gompels, Mark; De Wit, Stephane; Florence, Eric; Esser, Stefan; Raffi, François; Behrens, Georg; Pozniak, Anton; Gatell, José M; Martínez, Esteban. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 76:9(2021), pp. 2380-2393. [10.1093/jac/dkab158]
Abstract:
Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomarkers is unknown.
Tipologia CRIS:
Articolo su rivista
Elenco autori:
González-Cordón, Ana; Assoumou, Lambert; Moyle, Graeme; Waters, Laura; Johnson, Margaret; Domingo, Pere; Fox, Julie; Stellbrink, Hans-Jürgen; Guaraldi, Giovanni; Masiá, Mar; Gompels, Mark; De Wit, Stephane; Florence, Eric; Esser, Stefan; Raffi, François; Behrens, Georg; Pozniak, Anton; Gatell, José M; Martínez, Esteban
Link alla scheda completa:
Pubblicato in: